NervGen Announces "At-The-Market" Equity Program
Portfolio Pulse from
NervGen Pharma Corp. has announced an 'at-the-market' equity program allowing the company to issue and sell common shares through Stifel Nicolaus Canada Inc. This program provides NervGen with flexibility in raising capital as needed.
December 20, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
NervGen Pharma Corp. has initiated an 'at-the-market' equity program, allowing it to issue and sell shares as needed. This could lead to stock price fluctuations based on market conditions and investor perception.
The 'at-the-market' equity program allows NervGen to issue shares at its discretion, which can lead to stock price volatility depending on how the market perceives the dilution and the company's capital needs.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100